Mark du Toit from OysterCatcher Investments and Jean Pierre Verster from Protea Capital Management talk to Business Day TV
25 November 2020 - 11:21
byBusiness Day TV
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Du Toit said: “I’m going with Absa, they came out with a very detailed trading update which bodes well for building confidence in the sector. We saw their credit-loss ratio and they put through a large management overlay provision in the half year results and I think we will continue to see their credit-loss ratio reducing over the next three years.”
Verster said: “My stock is Amgen; it’s a US-listed biotech company that makes a biotech different from a pharma company. Their drugs are far more difficult to copy. They focus on certain drugs for arthritis, cancer, asthma and a few others.”
Mark du Toit from OysterCatcher Investments and Jean Pierre Verster from Protea Capital Management talk to Business Day TV
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Stock Watch
WATCH: Stock picks — Absa and Amgen
Mark du Toit from OysterCatcher Investments and Jean Pierre Verster from Protea Capital Management talk to Business Day TV
Mark du Toit from OysterCatcher Investments chose Absa as his stock pick of the day and Jean Pierre Verster from Protea Capital Management chose Amgen.
Du Toit said: “I’m going with Absa, they came out with a very detailed trading update which bodes well for building confidence in the sector. We saw their credit-loss ratio and they put through a large management overlay provision in the half year results and I think we will continue to see their credit-loss ratio reducing over the next three years.”
Verster said: “My stock is Amgen; it’s a US-listed biotech company that makes a biotech different from a pharma company. Their drugs are far more difficult to copy. They focus on certain drugs for arthritis, cancer, asthma and a few others.”
Mark du Toit from OysterCatcher Investments and Jean Pierre Verster from Protea Capital Management talk to Business Day TV
Reduce fraud and improve efficiency with Absa’s digital cash management solutions
Income funds: scraping a return on your cash
CHRIS GILMOUR: Demise of SA widows and orphans stocks drives investors offshore
Where 17 of SA’s top investment managers would invest R10m today
Pharma firms Astellas and Amgen to pay $125m after probe in co-payment scheme
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.